Biozenta focuses on technology for development and backward integration for its Oncology Active Pharmaceuticals Ingredients. Biozenta's Oncology API business is boosted by its R&D centre based at UNA, H.P., where a team of dedicated scientists is continuously working to develop cost-effective and non-infringing chemical processes following regulatory guidelines.

Biozenta R&D centre is fully equipped with current safety equipment, including an isolator lab and a separate facility for hydrogenation reactions, as well as unique provisions for low and high-temperature reactions (-80 to +250 C) and cyanation expertise.

Every product undergoes validation steps at the lab, pilot, and plant scales before commercialization to ensure cost-effectiveness and quality attributes for the market and therapeutic domain.